Comparison of the effectiveness of cefazolin and vancomycin in preventing infection in spinal fusion surgery.

Comparison of the effectiveness of cefazolin and vancomycin in preventing surgical site infections in patients undergoing spinal fusion surgery

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250508065643N1

Enrollment

Registered

2025-05-29

Start date

2025-05-31

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

spinal fusion. Disease of spinal cord, unspecified

Interventions

Intervention 1: First intervention group: 41 patients will receive 2 grams of cefazolin (Dana-Iran) intravenously for 6 to 24 hours after spinal fusion surgery. Patients in this group will also receiv

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Candidates for spinal fusion surgery Body mass index less than 30 Over 18 years old

Exclusion criteria

Exclusion criteria: Sensitivity to cefazolin and vancomycin

Design outcomes

Primary

Measure	Time frame
Surgical site infections (SSI). Timepoint: 1, 5, 15, 30, and 60 days after surgery. Method of measurement: Clinical examination according to CDC (Centers for Disease Control and Prevention) criteria.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohamadsaleh Mohamadi

Arak University of Medical Sciences

Dr.saleh_4046@yahoo.com+98 86 3313 4755

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026